Analysts’ Opinions Are Mixed on These Healthcare Stocks: Quest Diagnostics (DGX) and Inventiva (IVA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Quest Diagnostics (DGX – Research Report) and Inventiva (IVA – Research Report).

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Quest Diagnostics (DGX)

J.P. Morgan analyst Lisa Gill maintained a Hold rating on Quest Diagnostics today and set a price target of $190.00. The company’s shares closed last Wednesday at $180.89.

According to TipRanks.com, Gill is a 5-star analyst with an average return of 10.2% and a 61.7% success rate. Gill covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Privia Health Group, and Labcorp Holdings. ;'>

Quest Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $191.33, representing a 5.4% upside. In a report issued on October 2, Barclays also maintained a Hold rating on the stock with a $190.00 price target.

See the top stocks recommended by analysts >>

Inventiva (IVA)

Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Inventiva today and set a price target of $17.00. The company’s shares closed last Wednesday at $5.36.

According to TipRanks.com, Samimy is a 5-star analyst with an average return of 12.2% and a 49.4% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Mineralys Therapeutics, Inc., and Supernus Pharmaceuticals. ;'>

Inventiva has an analyst consensus of Strong Buy, with a price target consensus of $18.33, a 231.5% upside from current levels. In a report issued on September 29, Canaccord Genuity also maintained a Buy rating on the stock with a $20.00 price target.

Read More on DGX:

Disclaimer & DisclosureReport an Issue

• Quest Diagnostics price target raised to $190 from $185 at Evercore ISI
• Quest Diagnostics price target raised to $190 from $185 at Barclays
• Guardant Health, Quest Diagnostics announce blood-based screening test pact
• Quest Diagnostics partners with Epic for streamlined laboratory testing
• Haystack Oncology, Rutgers Cancer Institute collaborate to study Haystack MRD